Biocept, Inc.
Biocept, Inc. BIOC Peers
See (BIOC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOC | $0.43 | N/A | 450786.00 | -0.01 | -$48.17 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.76B | 146.01 | $8.64 | +0.57% |
| TMO | $405.83 | -5.39% | 153.20B | 23.83 | $17.03 | +0.37% |
| DHR | $187.81 | -4.48% | 134.41B | 36.40 | $5.16 | +0.57% |
| IDXX | $509.42 | +0.06% | 40.97B | 46.99 | $10.84 | N/A |
| A | $111.51 | -3.39% | 31.79B | 25.52 | $4.37 | +0.84% |
| IQV | $141.82 | -5.88% | 24.53B | 19.37 | $7.32 | N/A |
| MTD | $1,117.13 | -5.09% | 23.22B | 27.91 | $40.02 | N/A |
| NTRA | $151.34 | -0.62% | 20.67B | -102.26 | -$1.48 | N/A |
| WAT | $345.29 | -3.82% | 20.55B | 31.33 | $11.02 | N/A |
Stock Comparison
BIOC vs DHR-PB Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, DHR-PB has a market cap of 916.76B. Regarding current trading prices, BIOC is priced at $0.43, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BIOC's ROE is -1.38%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, BIOC is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs TMO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, TMO has a market cap of 153.20B. Regarding current trading prices, BIOC is priced at $0.43, while TMO trades at $405.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TMO's P/E ratio is 23.83. In terms of profitability, BIOC's ROE is -1.38%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BIOC is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs DHR Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, DHR has a market cap of 134.41B. Regarding current trading prices, BIOC is priced at $0.43, while DHR trades at $187.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DHR's P/E ratio is 36.40. In terms of profitability, BIOC's ROE is -1.38%, compared to DHR's ROE of +0.07%. Regarding short-term risk, BIOC is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs IDXX Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, IDXX has a market cap of 40.97B. Regarding current trading prices, BIOC is priced at $0.43, while IDXX trades at $509.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas IDXX's P/E ratio is 46.99. In terms of profitability, BIOC's ROE is -1.38%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, BIOC is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs A Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, A has a market cap of 31.79B. Regarding current trading prices, BIOC is priced at $0.43, while A trades at $111.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas A's P/E ratio is 25.52. In terms of profitability, BIOC's ROE is -1.38%, compared to A's ROE of +0.21%. Regarding short-term risk, BIOC is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs IQV Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, IQV has a market cap of 24.53B. Regarding current trading prices, BIOC is priced at $0.43, while IQV trades at $141.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas IQV's P/E ratio is 19.37. In terms of profitability, BIOC's ROE is -1.38%, compared to IQV's ROE of +0.21%. Regarding short-term risk, BIOC is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs MTD Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, MTD has a market cap of 23.22B. Regarding current trading prices, BIOC is priced at $0.43, while MTD trades at $1,117.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MTD's P/E ratio is 27.91. In terms of profitability, BIOC's ROE is -1.38%, compared to MTD's ROE of +1.21%. Regarding short-term risk, BIOC is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs NTRA Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NTRA has a market cap of 20.67B. Regarding current trading prices, BIOC is priced at $0.43, while NTRA trades at $151.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NTRA's P/E ratio is -102.26. In terms of profitability, BIOC's ROE is -1.38%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, BIOC is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs WAT Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, WAT has a market cap of 20.55B. Regarding current trading prices, BIOC is priced at $0.43, while WAT trades at $345.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas WAT's P/E ratio is 31.33. In terms of profitability, BIOC's ROE is -1.38%, compared to WAT's ROE of +0.39%. Regarding short-term risk, BIOC is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs DGX Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, DGX has a market cap of 19.25B. Regarding current trading prices, BIOC is priced at $0.43, while DGX trades at $172.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DGX's P/E ratio is 21.78. In terms of profitability, BIOC's ROE is -1.38%, compared to DGX's ROE of +0.13%. Regarding short-term risk, BIOC is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs PKI Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PKI has a market cap of 14.46B. Regarding current trading prices, BIOC is priced at $0.43, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PKI's P/E ratio is 41.45. In terms of profitability, BIOC's ROE is -1.38%, compared to PKI's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ILMN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ILMN has a market cap of 12.38B. Regarding current trading prices, BIOC is priced at $0.43, while ILMN trades at $78.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ILMN's P/E ratio is -12.86. In terms of profitability, BIOC's ROE is -1.38%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, BIOC is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs TEM Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, TEM has a market cap of 10.89B. Regarding current trading prices, BIOC is priced at $0.43, while TEM trades at $64.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TEM's P/E ratio is -12.55. In terms of profitability, BIOC's ROE is -1.38%, compared to TEM's ROE of -5.31%. Regarding short-term risk, BIOC is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs RVTY Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, RVTY has a market cap of 10.73B. Regarding current trading prices, BIOC is priced at $0.43, while RVTY trades at $91.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas RVTY's P/E ratio is 37.61. In terms of profitability, BIOC's ROE is -1.38%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, BIOC is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ICLR Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ICLR has a market cap of 10.68B. Regarding current trading prices, BIOC is priced at $0.43, while ICLR trades at $132.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ICLR's P/E ratio is 14.42. In terms of profitability, BIOC's ROE is -1.38%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs EXAS Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, EXAS has a market cap of 10.35B. Regarding current trading prices, BIOC is priced at $0.43, while EXAS trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas EXAS's P/E ratio is -9.92. In terms of profitability, BIOC's ROE is -1.38%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, BIOC is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs QGEN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, QGEN has a market cap of 8.89B. Regarding current trading prices, BIOC is priced at $0.43, while QGEN trades at $41.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas QGEN's P/E ratio is 108.26. In terms of profitability, BIOC's ROE is -1.38%, compared to QGEN's ROE of +0.02%. Regarding short-term risk, BIOC is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs MEDP Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, MEDP has a market cap of 8.38B. Regarding current trading prices, BIOC is priced at $0.43, while MEDP trades at $291.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MEDP's P/E ratio is 22.29. In terms of profitability, BIOC's ROE is -1.38%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, BIOC is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CRL Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CRL has a market cap of 6.82B. Regarding current trading prices, BIOC is priced at $0.43, while CRL trades at $138.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CRL's P/E ratio is -231.58. In terms of profitability, BIOC's ROE is -1.38%, compared to CRL's ROE of -0.01%. Regarding short-term risk, BIOC is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs GH Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, GH has a market cap of 5.04B. Regarding current trading prices, BIOC is priced at $0.43, while GH trades at $40.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GH's P/E ratio is -12.01. In terms of profitability, BIOC's ROE is -1.38%, compared to GH's ROE of +3.69%. Regarding short-term risk, BIOC is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs RDNT Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, RDNT has a market cap of 4.47B. Regarding current trading prices, BIOC is priced at $0.43, while RDNT trades at $60.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas RDNT's P/E ratio is 1508.50. In terms of profitability, BIOC's ROE is -1.38%, compared to RDNT's ROE of +0.02%. Regarding short-term risk, BIOC is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs SYNH Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, SYNH has a market cap of 4.46B. Regarding current trading prices, BIOC is priced at $0.43, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BIOC's ROE is -1.38%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs SHC Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, SHC has a market cap of 3.35B. Regarding current trading prices, BIOC is priced at $0.43, while SHC trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SHC's P/E ratio is 73.88. In terms of profitability, BIOC's ROE is -1.38%, compared to SHC's ROE of +0.06%. Regarding short-term risk, BIOC is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs OLK Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, OLK has a market cap of 3.24B. Regarding current trading prices, BIOC is priced at $0.43, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OLK's P/E ratio is -96.59. In terms of profitability, BIOC's ROE is -1.38%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BIOC is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs TWST Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, TWST has a market cap of 1.77B. Regarding current trading prices, BIOC is priced at $0.43, while TWST trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TWST's P/E ratio is -9.08. In terms of profitability, BIOC's ROE is -1.38%, compared to TWST's ROE of -0.41%. Regarding short-term risk, BIOC is more volatile compared to TWST. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs VIVO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, VIVO has a market cap of 1.49B. Regarding current trading prices, BIOC is priced at $0.43, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas VIVO's P/E ratio is 21.09. In terms of profitability, BIOC's ROE is -1.38%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, BIOC is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs NEOG Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NEOG has a market cap of 1.38B. Regarding current trading prices, BIOC is priced at $0.43, while NEOG trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NEOG's P/E ratio is -2.86. In terms of profitability, BIOC's ROE is -1.38%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, BIOC is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs GRAL Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, GRAL has a market cap of 1.16B. Regarding current trading prices, BIOC is priced at $0.43, while GRAL trades at $32.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GRAL's P/E ratio is -0.52. In terms of profitability, BIOC's ROE is -1.38%, compared to GRAL's ROE of -0.70%. Regarding short-term risk, BIOC is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs OPK Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, OPK has a market cap of 999.25M. Regarding current trading prices, BIOC is priced at $0.43, while OPK trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OPK's P/E ratio is -21.00. In terms of profitability, BIOC's ROE is -1.38%, compared to OPK's ROE of -0.03%. Regarding short-term risk, BIOC is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CDNA Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CDNA has a market cap of 892.00M. Regarding current trading prices, BIOC is priced at $0.43, while CDNA trades at $16.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CDNA's P/E ratio is 14.30. In terms of profitability, BIOC's ROE is -1.38%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, BIOC is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs FLGT Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, FLGT has a market cap of 598.52M. Regarding current trading prices, BIOC is priced at $0.43, while FLGT trades at $19.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas FLGT's P/E ratio is -14.78. In terms of profitability, BIOC's ROE is -1.38%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, BIOC is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs GRALV Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, GRALV has a market cap of 579.39M. Regarding current trading prices, BIOC is priced at $0.43, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GRALV's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to GRALV's ROE of N/A. Regarding short-term risk, BIOC is more volatile compared to GRALV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CSTL Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CSTL has a market cap of 471.20M. Regarding current trading prices, BIOC is priced at $0.43, while CSTL trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CSTL's P/E ratio is -85.89. In terms of profitability, BIOC's ROE is -1.38%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, BIOC is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs PSNL Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PSNL has a market cap of 425.73M. Regarding current trading prices, BIOC is priced at $0.43, while PSNL trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PSNL's P/E ratio is -3.74. In terms of profitability, BIOC's ROE is -1.38%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, BIOC is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs LAB Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, LAB has a market cap of 406.41M. Regarding current trading prices, BIOC is priced at $0.43, while LAB trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LAB's P/E ratio is -3.34. In terms of profitability, BIOC's ROE is -1.38%, compared to LAB's ROE of -0.28%. Regarding short-term risk, BIOC is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CO has a market cap of 400.08M. Regarding current trading prices, BIOC is priced at $0.43, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CO's P/E ratio is 5.06. In terms of profitability, BIOC's ROE is -1.38%, compared to CO's ROE of +0.18%. Regarding short-term risk, BIOC is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs MYGN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, MYGN has a market cap of 353.96M. Regarding current trading prices, BIOC is priced at $0.43, while MYGN trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MYGN's P/E ratio is -3.43. In terms of profitability, BIOC's ROE is -1.38%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, BIOC is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs FLDM Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, FLDM has a market cap of 294.19M. Regarding current trading prices, BIOC is priced at $0.43, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BIOC's ROE is -1.38%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, BIOC is more volatile compared to FLDM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs STIM Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, STIM has a market cap of 283.03M. Regarding current trading prices, BIOC is priced at $0.43, while STIM trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas STIM's P/E ratio is -3.26. In terms of profitability, BIOC's ROE is -1.38%, compared to STIM's ROE of -2.09%. Regarding short-term risk, BIOC is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs NEO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NEO has a market cap of 204.88M. Regarding current trading prices, BIOC is priced at $0.43, while NEO trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NEO's P/E ratio is -13.05. In terms of profitability, BIOC's ROE is -1.38%, compared to NEO's ROE of -0.09%. Regarding short-term risk, BIOC is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ACRS Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ACRS has a market cap of 127.77M. Regarding current trading prices, BIOC is priced at $0.43, while ACRS trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ACRS's P/E ratio is -0.74. In terms of profitability, BIOC's ROE is -1.38%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, BIOC is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs GTH Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, GTH has a market cap of 127.29M. Regarding current trading prices, BIOC is priced at $0.43, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GTH's P/E ratio is -1.11. In terms of profitability, BIOC's ROE is -1.38%, compared to GTH's ROE of +0.00%. Regarding short-term risk, BIOC is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs XGN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, XGN has a market cap of 124.27M. Regarding current trading prices, BIOC is priced at $0.43, while XGN trades at $5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas XGN's P/E ratio is -6.93. In terms of profitability, BIOC's ROE is -1.38%, compared to XGN's ROE of -1.34%. Regarding short-term risk, BIOC is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs GENE Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, GENE has a market cap of 111.24M. Regarding current trading prices, BIOC is priced at $0.43, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GENE's P/E ratio is -38.25. In terms of profitability, BIOC's ROE is -1.38%, compared to GENE's ROE of -3.62%. Regarding short-term risk, BIOC is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs MDXH Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, MDXH has a market cap of 88.11M. Regarding current trading prices, BIOC is priced at $0.43, while MDXH trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MDXH's P/E ratio is -1.53. In terms of profitability, BIOC's ROE is -1.38%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, BIOC is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs SERA Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, SERA has a market cap of 82.59M. Regarding current trading prices, BIOC is priced at $0.43, while SERA trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SERA's P/E ratio is -2.39. In terms of profitability, BIOC's ROE is -1.38%, compared to SERA's ROE of -0.58%. Regarding short-term risk, BIOC is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs PRE Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PRE has a market cap of 75.54M. Regarding current trading prices, BIOC is priced at $0.43, while PRE trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PRE's P/E ratio is -1.56. In terms of profitability, BIOC's ROE is -1.38%, compared to PRE's ROE of -0.25%. Regarding short-term risk, BIOC is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs NOTV Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NOTV has a market cap of 70.08M. Regarding current trading prices, BIOC is priced at $0.43, while NOTV trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NOTV's P/E ratio is -0.65. In terms of profitability, BIOC's ROE is -1.38%, compared to NOTV's ROE of -0.52%. Regarding short-term risk, BIOC is more volatile compared to NOTV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs PRENW Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PRENW has a market cap of 62.21M. Regarding current trading prices, BIOC is priced at $0.43, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PRENW's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, BIOC is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs VNRX Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, VNRX has a market cap of 48.37M. Regarding current trading prices, BIOC is priced at $0.43, while VNRX trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas VNRX's P/E ratio is -1.55. In terms of profitability, BIOC's ROE is -1.38%, compared to VNRX's ROE of +1.29%. Regarding short-term risk, BIOC is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs OPGN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, OPGN has a market cap of 47.32M. Regarding current trading prices, BIOC is priced at $0.43, while OPGN trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OPGN's P/E ratio is -0.30. In terms of profitability, BIOC's ROE is -1.38%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, BIOC is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs BDSX Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BDSX has a market cap of 32.22M. Regarding current trading prices, BIOC is priced at $0.43, while BDSX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BDSX's P/E ratio is -0.67. In terms of profitability, BIOC's ROE is -1.38%, compared to BDSX's ROE of -2.16%. Regarding short-term risk, BIOC is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs STRRP Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, STRRP has a market cap of 29.78M. Regarding current trading prices, BIOC is priced at $0.43, while STRRP trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas STRRP's P/E ratio is -4.65. In terms of profitability, BIOC's ROE is -1.38%, compared to STRRP's ROE of -0.18%. Regarding short-term risk, BIOC is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs DRIO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, DRIO has a market cap of 27.43M. Regarding current trading prices, BIOC is priced at $0.43, while DRIO trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DRIO's P/E ratio is -1.08. In terms of profitability, BIOC's ROE is -1.38%, compared to DRIO's ROE of -0.47%. Regarding short-term risk, BIOC is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs AKU Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, AKU has a market cap of 26.27M. Regarding current trading prices, BIOC is priced at $0.43, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas AKU's P/E ratio is -0.13. In terms of profitability, BIOC's ROE is -1.38%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BIOC is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs ADVB Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ADVB has a market cap of 25.75M. Regarding current trading prices, BIOC is priced at $0.43, while ADVB trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ADVB's P/E ratio is -8.50. In terms of profitability, BIOC's ROE is -1.38%, compared to ADVB's ROE of -2.41%. Regarding short-term risk, BIOC is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs CEMI Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CEMI has a market cap of 16.71M. Regarding current trading prices, BIOC is priced at $0.43, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BIOC's ROE is -1.38%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BIOC is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ENZ Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ENZ has a market cap of 16.44M. Regarding current trading prices, BIOC is priced at $0.43, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BIOC's ROE is -1.38%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BIOC is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs PMD Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PMD has a market cap of 15.74M. Regarding current trading prices, BIOC is priced at $0.43, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PMD's P/E ratio is -5.24. In terms of profitability, BIOC's ROE is -1.38%, compared to PMD's ROE of -0.33%. Regarding short-term risk, BIOC is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ME Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ME has a market cap of 13.34M. Regarding current trading prices, BIOC is priced at $0.43, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ME's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to ME's ROE of -3.04%. Regarding short-term risk, BIOC is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs BNGO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BNGO has a market cap of 11.60M. Regarding current trading prices, BIOC is priced at $0.43, while BNGO trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BNGO's P/E ratio is -0.04. In terms of profitability, BIOC's ROE is -1.38%, compared to BNGO's ROE of -1.81%. Regarding short-term risk, BIOC is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs PRPO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, PRPO has a market cap of 10.51M. Regarding current trading prices, BIOC is priced at $0.43, while PRPO trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PRPO's P/E ratio is -2.37. In terms of profitability, BIOC's ROE is -1.38%, compared to PRPO's ROE of -0.35%. Regarding short-term risk, BIOC is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CNTG Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CNTG has a market cap of 9.43M. Regarding current trading prices, BIOC is priced at $0.43, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BIOC's ROE is -1.38%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BIOC is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs INBS Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, INBS has a market cap of 8.75M. Regarding current trading prices, BIOC is priced at $0.43, while INBS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas INBS's P/E ratio is 10.71. In terms of profitability, BIOC's ROE is -1.38%, compared to INBS's ROE of -1.72%. Regarding short-term risk, BIOC is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs STRR Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, STRR has a market cap of 7.53M. Regarding current trading prices, BIOC is priced at $0.43, while STRR trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas STRR's P/E ratio is -0.71. In terms of profitability, BIOC's ROE is -1.38%, compared to STRR's ROE of -0.18%. Regarding short-term risk, BIOC is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs MYNZ Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, MYNZ has a market cap of 6.88M. Regarding current trading prices, BIOC is priced at $0.43, while MYNZ trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MYNZ's P/E ratio is -0.10. In terms of profitability, BIOC's ROE is -1.38%, compared to MYNZ's ROE of -16.99%. Regarding short-term risk, BIOC is more volatile compared to MYNZ. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs CHEK Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, CHEK has a market cap of 5.67M. Regarding current trading prices, BIOC is priced at $0.43, while CHEK trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CHEK's P/E ratio is -0.45. In terms of profitability, BIOC's ROE is -1.38%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, BIOC is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs NVTA Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NVTA has a market cap of 5.44M. Regarding current trading prices, BIOC is priced at $0.43, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to NVTA's ROE of +1.79%. Regarding short-term risk, BIOC is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs APDN Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, APDN has a market cap of 5.44M. Regarding current trading prices, BIOC is priced at $0.43, while APDN trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas APDN's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to APDN's ROE of -1.00%. Regarding short-term risk, BIOC is more volatile compared to APDN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs BGLC Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BGLC has a market cap of 5.34M. Regarding current trading prices, BIOC is priced at $0.43, while BGLC trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BGLC's P/E ratio is -3.30. In terms of profitability, BIOC's ROE is -1.38%, compared to BGLC's ROE of -0.17%. Regarding short-term risk, BIOC is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs LMDXW Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, LMDXW has a market cap of 5.10M. Regarding current trading prices, BIOC is priced at $0.43, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BIOC is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs LMDX Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, LMDX has a market cap of 5.10M. Regarding current trading prices, BIOC is priced at $0.43, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BIOC's ROE is -1.38%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BIOC is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs TTOO Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, TTOO has a market cap of 4.35M. Regarding current trading prices, BIOC is priced at $0.43, while TTOO trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TTOO's P/E ratio is -5.17. In terms of profitability, BIOC's ROE is -1.38%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, BIOC is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs BIAF Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BIAF has a market cap of 4.11M. Regarding current trading prices, BIOC is priced at $0.43, while BIAF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BIAF's P/E ratio is -0.30. In terms of profitability, BIOC's ROE is -1.38%, compared to BIAF's ROE of -2.51%. Regarding short-term risk, BIOC is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs BIAFW Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BIAFW has a market cap of 3.65M. Regarding current trading prices, BIOC is priced at $0.43, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BIAFW's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to BIAFW's ROE of -2.51%. Regarding short-term risk, BIOC is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs DMTK Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, DMTK has a market cap of 3.29M. Regarding current trading prices, BIOC is priced at $0.43, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BIOC's ROE is -1.38%, compared to DMTK's ROE of -1.39%. Regarding short-term risk, BIOC is more volatile compared to DMTK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs ISPC Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, ISPC has a market cap of 2.95M. Regarding current trading prices, BIOC is priced at $0.43, while ISPC trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ISPC's P/E ratio is -0.07. In terms of profitability, BIOC's ROE is -1.38%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, BIOC is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs AWH Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, AWH has a market cap of 2.89M. Regarding current trading prices, BIOC is priced at $0.43, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas AWH's P/E ratio is -0.09. In terms of profitability, BIOC's ROE is -1.38%, compared to AWH's ROE of +5.16%. Regarding short-term risk, BIOC is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs BNR Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, BNR has a market cap of 2.81M. Regarding current trading prices, BIOC is priced at $0.43, while BNR trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BNR's P/E ratio is -0.56. In terms of profitability, BIOC's ROE is -1.38%, compared to BNR's ROE of -0.53%. Regarding short-term risk, BIOC is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs SQL Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, SQL has a market cap of 2.51M. Regarding current trading prices, BIOC is priced at $0.43, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SQL's P/E ratio is -0.40. In terms of profitability, BIOC's ROE is -1.38%, compared to SQL's ROE of -0.67%. Regarding short-term risk, BIOC is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for BIOC.
BIOC vs NDRA Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, NDRA has a market cap of 1.75M. Regarding current trading prices, BIOC is priced at $0.43, while NDRA trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NDRA's P/E ratio is -0.05. In terms of profitability, BIOC's ROE is -1.38%, compared to NDRA's ROE of -2.11%. Regarding short-term risk, BIOC is more volatile compared to NDRA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs HTGM Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, HTGM has a market cap of 1.06M. Regarding current trading prices, BIOC is priced at $0.43, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BIOC is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs SQLLW Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, SQLLW has a market cap of 837087.00. Regarding current trading prices, BIOC is priced at $0.43, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, BIOC's ROE is -1.38%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, BIOC is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.
BIOC vs TRIB Comparison
BIOC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450786.00. In comparison, TRIB has a market cap of 454820.00. Regarding current trading prices, BIOC is priced at $0.43, while TRIB trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TRIB's P/E ratio is -0.36. In terms of profitability, BIOC's ROE is -1.38%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, BIOC is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for BIOC.